Cargando…

Pharmacist-directed vancomycin therapeutic drug monitoring in pediatric patients: a collaborative-practice model

BACKGROUND: Therapeutic drug monitoring (TDM) of Vancomycin (VCM) is required to prevent inappropriate dosage-associated bacterial resistance, therapeutic failure, and toxicities in pediatrics. Anecdotal experience and studies show that many healthcare institutions confront barriers while implementi...

Descripción completa

Detalles Bibliográficos
Autores principales: Hussain, Kashif, Ikram, Rahila, Ambreen, Gul, Salat, Muhammad Sohail
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8630891/
https://www.ncbi.nlm.nih.gov/pubmed/34847951
http://dx.doi.org/10.1186/s40545-021-00383-y
_version_ 1784607450883686400
author Hussain, Kashif
Ikram, Rahila
Ambreen, Gul
Salat, Muhammad Sohail
author_facet Hussain, Kashif
Ikram, Rahila
Ambreen, Gul
Salat, Muhammad Sohail
author_sort Hussain, Kashif
collection PubMed
description BACKGROUND: Therapeutic drug monitoring (TDM) of Vancomycin (VCM) is required to prevent inappropriate dosage-associated bacterial resistance, therapeutic failure, and toxicities in pediatrics. Anecdotal experience and studies show that many healthcare institutions confront barriers while implementing TDM services, this study aimed to assess a pharmacist-directed VCM–TDM service for optimizing patient care in our institution. MATERIALS AND METHODS: Patients aged 1 month–18 years who received intravenous VCM were included in this quasi-experimental study. The pre-implementation phase (March–June 2018) consisted of retrospective assessment of pediatric patients, the interventional phase (July 2018 to February 2020) included educational programs and the post-implementation phase (March–June 2020) evaluated the participants based on pharmacist-directed VCM–TDM services as a collaborative-practice model including clinical and inpatient pharmacists to provide 24/7 TDM services. Outcomes of the study included the mean difference in the number of optimal (i) prescribed initial VCM doses (primary) (ii) dosage adjustments and (iii) VCM-sampling time (secondary). After ethical approval, data were collected retrospectively. RESULTS: A hundred patients were there in each phase. The number of cases who were correctly prescribed initial VCM doses was significantly higher in the post-implementation phase, mean difference of 0.22, [95% CI (0.142–0.0.358), p < 0.0001]. Patients who had correct dosage adjustments in the post-implementation phase also had higher statistical significance, mean difference of 0.29, [95% CI (0.152–0.423), p < 0.05]. More correct practices of VCM-levels timing were observed in the post-implementation phase, mean difference of 0.15, [95% CI (− 0.053–0.264), p = 0.079]. CONCLUSION: This study showed the significant role of pharmacist-directed TDM services to optimize the correct prescribing of initial VCM doses and dose adjustments.
format Online
Article
Text
id pubmed-8630891
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-86308912021-12-01 Pharmacist-directed vancomycin therapeutic drug monitoring in pediatric patients: a collaborative-practice model Hussain, Kashif Ikram, Rahila Ambreen, Gul Salat, Muhammad Sohail J Pharm Policy Pract Research BACKGROUND: Therapeutic drug monitoring (TDM) of Vancomycin (VCM) is required to prevent inappropriate dosage-associated bacterial resistance, therapeutic failure, and toxicities in pediatrics. Anecdotal experience and studies show that many healthcare institutions confront barriers while implementing TDM services, this study aimed to assess a pharmacist-directed VCM–TDM service for optimizing patient care in our institution. MATERIALS AND METHODS: Patients aged 1 month–18 years who received intravenous VCM were included in this quasi-experimental study. The pre-implementation phase (March–June 2018) consisted of retrospective assessment of pediatric patients, the interventional phase (July 2018 to February 2020) included educational programs and the post-implementation phase (March–June 2020) evaluated the participants based on pharmacist-directed VCM–TDM services as a collaborative-practice model including clinical and inpatient pharmacists to provide 24/7 TDM services. Outcomes of the study included the mean difference in the number of optimal (i) prescribed initial VCM doses (primary) (ii) dosage adjustments and (iii) VCM-sampling time (secondary). After ethical approval, data were collected retrospectively. RESULTS: A hundred patients were there in each phase. The number of cases who were correctly prescribed initial VCM doses was significantly higher in the post-implementation phase, mean difference of 0.22, [95% CI (0.142–0.0.358), p < 0.0001]. Patients who had correct dosage adjustments in the post-implementation phase also had higher statistical significance, mean difference of 0.29, [95% CI (0.152–0.423), p < 0.05]. More correct practices of VCM-levels timing were observed in the post-implementation phase, mean difference of 0.15, [95% CI (− 0.053–0.264), p = 0.079]. CONCLUSION: This study showed the significant role of pharmacist-directed TDM services to optimize the correct prescribing of initial VCM doses and dose adjustments. BioMed Central 2021-11-30 /pmc/articles/PMC8630891/ /pubmed/34847951 http://dx.doi.org/10.1186/s40545-021-00383-y Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Hussain, Kashif
Ikram, Rahila
Ambreen, Gul
Salat, Muhammad Sohail
Pharmacist-directed vancomycin therapeutic drug monitoring in pediatric patients: a collaborative-practice model
title Pharmacist-directed vancomycin therapeutic drug monitoring in pediatric patients: a collaborative-practice model
title_full Pharmacist-directed vancomycin therapeutic drug monitoring in pediatric patients: a collaborative-practice model
title_fullStr Pharmacist-directed vancomycin therapeutic drug monitoring in pediatric patients: a collaborative-practice model
title_full_unstemmed Pharmacist-directed vancomycin therapeutic drug monitoring in pediatric patients: a collaborative-practice model
title_short Pharmacist-directed vancomycin therapeutic drug monitoring in pediatric patients: a collaborative-practice model
title_sort pharmacist-directed vancomycin therapeutic drug monitoring in pediatric patients: a collaborative-practice model
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8630891/
https://www.ncbi.nlm.nih.gov/pubmed/34847951
http://dx.doi.org/10.1186/s40545-021-00383-y
work_keys_str_mv AT hussainkashif pharmacistdirectedvancomycintherapeuticdrugmonitoringinpediatricpatientsacollaborativepracticemodel
AT ikramrahila pharmacistdirectedvancomycintherapeuticdrugmonitoringinpediatricpatientsacollaborativepracticemodel
AT ambreengul pharmacistdirectedvancomycintherapeuticdrugmonitoringinpediatricpatientsacollaborativepracticemodel
AT salatmuhammadsohail pharmacistdirectedvancomycintherapeuticdrugmonitoringinpediatricpatientsacollaborativepracticemodel